Food and Drug Administration (FDA)
NEWS
Months after GlaxoSmithKline unveiled positive long-term data that showed Nucala is an effective treatment for patients with severe asthma, a U.S. FDA staff report is casting doubts on its potential as a treatment for chronic obstructive pulmonary disease (COPD).
GlaxoSmithKline continues to make headway in the development of two-drug regimens to benefit HIV patients – even those who have high levels of the virus.
Shares of Eli Lilly jumped in premarket trading after the company reported total revenue of $6.35 billion for the second quarter, a 9 percent increase in revenue over the same period last year.
Celgene announced data from its Phase III AUGMENT clinical trial that compared Revlimid (lenalidomide) and rituximab to placebo in relapsed/refractory follicular and marginal zone lymphoma.
Despite positive Phase III clinical trial data for Allergan’s age-related macular degeneration drug, investors weren’t as positive about it.
BeiGene is starting off the week with a bang. Late Sunday the company announced positive preliminary topline results from its Phase II trial of tislelizumab, the company’s investigational checkpoint inhibitor for relapsed/refractory classical Hodgkin’s lymphoma (R/R cHL).
Shares of Agios Pharmaceuticals jumped this morning after the company said the FDA approved its oral leukemia treatment Tibsovo (ivosidenib). It’s the second approval for the company in less than a year.
The U.S. Food and Drug Administration is looking to address supply chain threats by potentially importing foreign drugs under a narrow scope.
Over the years there have been questions surrounding the efficacy of some medications used to treat mental health issues. Last year a Harvard professor argued on CBS’ 60 Minutes that there was little difference between a psychiatric drug and a placebo.
JOBS
IN THE PRESS